浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Systematic review on the design of randomized controlled trials about therapeutic drugs for rotavirus infection in children
- ZHONGGUO YAOFANG Vol. 34, Issue 14, Pages: 1761-1767(2023)
- 作者机构：
青岛大学附属妇女儿童医院/青岛市妇女儿童医院临床药学科，山东 青岛 266034
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.14.19
CLC： R978.7Published：30 July 2023，
Received：20 December 2022，
Revised：13 April 2023，
扫 描 看 全 文
高石曼,刘畅,闫美兴.儿童轮状病毒感染治疗药物随机对照试验设计的系统评价[J].中国药房,2023,34(14):1761-1767.
GAO Shiman,LIU Chang,YAN Meixing.Systematic review on the design of randomized controlled trials about therapeutic drugs for rotavirus infection in children[J].ZHONGGUO YAOFANG,2023,34(14):1761-1767.
高石曼,刘畅,闫美兴.儿童轮状病毒感染治疗药物随机对照试验设计的系统评价[J].中国药房,2023,34(14):1761-1767. DOI： 10.6039/j.issn.1001-0408.2023.14.19.
GAO Shiman,LIU Chang,YAN Meixing.Systematic review on the design of randomized controlled trials about therapeutic drugs for rotavirus infection in children[J].ZHONGGUO YAOFANG,2023,34(14):1761-1767. DOI： 10.6039/j.issn.1001-0408.2023.14.19.
摘要
目的
2
系统分析儿童轮状病毒感染治疗药物的相关临床研究，为提升临床试验实施过程的科学性和规范性提供参考。
方法
2
系统检索PubMed、the Cochrane Library和Embase数据库，纳入2000－2022年发表的儿童轮状病毒感染治疗药物随机对照试验（RCT）的英文文献。筛选文献、提取资料后，采用Cochrane系统评价员手册推荐的偏倚评价量表对纳入文献进行质量评价，对其研究目的、试验设计、受试者的选择与退出、干预措施、疗程、随访、有效性与安全性评价、试验结果等进行描述性分析。结果与
结论
2
共纳入17项RCT，共计1 345例儿童受试者。研究目的包括缓解轮状病毒感染引起的腹泻发作，促进粪便中轮状病毒脱落，改善脱水、发热、呕吐等临床症状，缩短住院时间等；所有研究均采用随机方法，均为单中心研究，多采用双盲设计（13项）和安慰剂对照（16项），且64.71%的研究有样本量估算；受试者的纳入与排除标准涉及腹泻发作情况、病毒检测情况、临床症状、病种、试验用药物等；干预措施包括益生菌（8项）、生物制剂（3项）、抗感染药（3项）等，疗程以1～5 d为主（13项）；58.82%的研究设计了随访；有效性评价主要针对腹泻发作情况，微生物学试验和粪便培养结果，脱水、发热及呕吐等临床症状，住院时间或症状持续时间等，指标评价标准包括Vesikari量表、WHO推荐标准及研究者相关记录等；有10项研究对不良事件/不良反应进行了观察；仅有1项研究列出了伦理批件号。纳入研究的文献信息涵盖了儿童轮状病毒感染治疗药物RCT设计的基本要素，但均为单中心研究，部分研究缺乏样本量估算依据及基础治疗之外的合并用药情况，质量有待提升。今后应进一步开展高质量的多中心临床试验，以客观测量指标为主要有效性结果，并重视伦理审查和药物安全性评价。
Abstract
OBJECTIVE
2
To systematically analyze the related clinical research of therapeutic drugs for rotavirus infection in children， and to provide reference for the improvement of scientific and normative implementation in clinical trials.
METHODS
2
PubMed， the Cochrane Library and Embase databases were systematically searched， and English literature on randomized controlled trials （RCTs） about therapeutic drugs for pediatric rotavirus infection published between 2000 and 2022 was included. After literature screening and data extraction， the quality of the included literature was evaluated using the bias risk assessment scale recommended by Cochrane Handbook for Systematic Reviews. The research objectives， overall design， subject inclusion and exclusion criteria， interventions， course of treatment， follow-up visits， efficacy and safety evaluations， and results were analyzed descriptively. RESULTS &
CONCLUSIONS
2
A total of 17 RCTs were included， involving 1 345 subjects. The purpose included relieving rotavirus infection-induced diarrhea， promoting rotaviral shedding， improving clinical symptoms such as dehydration， fever， vomiting， and shortening hospital stays， etc. All trials were randomized and single-center studies， mostly double-blind （13 trials） and placebo-controlled （16 trials）， and 64.71% had sample size estimation. The inclusion and exclusion criteria included diarrhea attack， virus detection， clinical symptoms， disease types and drugs， etc. The interventions included probiotics （8 trials）， biological agents （3 trials）， anti-infective agents （3 trials）， etc. Most of treatment course was 1-5 days （13 trials）. A total of 58.82% were designed for follow-up. In the validity evaluation， diarrhea attack， microbiology test and fecal culture， clinical symptoms such as dehydration， fever and vomiting， length of hospital stays or duration of symptoms were included. Vesikari scale， WHO criteria and researcher evaluation were the evaluation criteria. In the safety evaluation， 10 trials were designed for adverse events/adverse reaction observation； only one trial listed ethical approval numbers. The information of literature included in the study covers the basic elements for the design of RCTs of drugs for rotavirus infection in children. Nevertheless， all are single-center studies. Partial studies lack the basis for sample size estimation and related contents of drug combination， and the quality needs to be improved. In the future， the high-quality multi-center clinical trials should be further conducted， with objective measurement indexes as the validity results， and the ethical review and safety evaluation should be emphasized.
关键词
轮状病毒感染儿童随机对照试验设计要素
Keywords
childrenrandomized controlled trialsdesign elements
references
ZHAO G W，REN X F. Rotavirus infections：mechanisms，prevention and treatment[J]. World Chin J Dig，2013，21（1）：60.
STANIFER M，BOULANT S. The origin of diarrhea in rotavirus infection[J]. Science，2020，370（6519）：909-910.
WIKSWO M E，PARASHAR U D，LOPMAN B，et al. Evidence for household transmission of rotavirus in the United States，2011-2016[J]. J Pediatric Infect Dis Soc，2020，9（2）：181-187.
李瑛.小儿轮状病毒肠炎流行病学特点及医院感染控制[J].现代预防医学，2014，41（8）：1506-1507.
ENGEVIK M A，BANKS L D，ENGEVIK K A，et al. Rotavirus infection induces glycan availability to promote ileum-specific changes in the microbiome aiding rotavirus virulence[J]. Gut Microbes，2020，11（5）：1324-1347.
FLOREZ I D，NIÑO-SERNA L F，BELTRÁN-ARROYAVE C P. Acute infectious diarrhea and gastroenteritis in children[J]. Curr Infect Dis Rep，2020，22（2）：4.
SEN A，NAMSA N D，FENG N G，et al. Rotavirus reprograms multiple interferon receptors and restricts their intestinal antiviral and inflammatory functions[J]. J Virol，2020，94（6）：e01775-19.
LAU Y L，FAN LEUNG T，SIRVAN CETIN B，et al. Safety and reactogenicity of a liquid formulation of human rotavirus vaccine（porcine circovirus-free）：a phase Ⅲ，observer-blind，randomized，multi-country study[J]. Vaccine，2022，40（14）：2184-2190.
GROOME M J，FAIRLIE L，MORRISON J，et al. Safety and immunogenicity of a parenteral trivalent P2-VP8 subu-nit rotavirus vaccine：a multisite，randomised，double-blind，placebo-controlled trial[J]. Lancet Infect Dis，2020，20（7）：851-863.
WU Z W，LI Q L，ZHOU H S，et al. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase Ⅰ clinical trial[J]. Hum Vaccin Immunother，2021，17（7）：2311-2318.
ABU-ELYAZEED R，KLEIN N P，MOERMAN L，et al. Concomitant administration of a liquid formulation of human rotavirus vaccine（porcine circovirus-free）with routine childhood vaccines in infants in the United States：results from a phase 3，randomized trial[J]. Vaccine，2021，39（10）：1534-1543.
BLACK R，FONTAINE O，LAMBERTI L，et al. Drivers of the reduction in childhood diarrhea mortality 1980-2015 and interventions to eliminate preventable diarrhea deaths by 2030[J]. J Glob Health，2019，9（2）：020801.
GUARINO A，AGUILAR J，BERKLEY J，et al. Acute gastroenteritis in children of the world：what needs to be done?[J]. J Pediatr Gastroenterol Nutr，2020，70（5）：694-701.
HIGGINS J P T，GREEN S. Assessing risk of bias in included studies：Cochrane handbook for systematic reviews of interventions 5.1.0[EB/OL]. [2022-05-10]. http：//www.handbook-5-1.cochrane.orghttp://www.handbook-5-1.cochrane.org.
NARAYANAPPA D. Randomized double blinded controlled trial to evaluate the efficacy and safety of Bifilac in patients with acute viral diarrhea[J]. Indian J Pediatr，2008，75（7）：709-713.
SARKER S A，JÄKEL M，SULTANA S，et al. Anti-rotavirus protein reduces stool output in infants with diarrhea：a randomized placebo-controlled trial[J]. Gastroenterology，2013，145（4）：740-748.e8.
HUANG Y F，LIU P Y，CHEN Y Y，et al. Three-combination probiotics therapy in children with salmonella and rotavirus gastroenteritis[J]. J Clin Gastroenterol，2014，48（1）：37-42.
FANG S B，LEE H C，HU J J，et al. Dose-dependent effect of Lactobacillus rhamnosus on quantitative reduction of faecal rotavirus shedding in children[J]. J Trop Pediatr，2009，55（5）：297-301.
ROSSIGNOL J F，ABU-ZEKRY M，HUSSEIN A，et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea：randomised double-blind placebo-controlled trial[J]. Lancet，2006，368（9530）：124-129.
SUBBOTINA M D，TIMCHENKO V N，VOROBYOV M M，et al. Effect of oral administration of tormentil root extract（Potentilla tormentilla）on rotavirus diarrhea in children：a randomized，double blind，controlled trial[J]. Pe-diatr Infect Dis J，2003，22（8）：706-711.
DAS S，GUPTA P K，DAS R R. Efficacy and safety of Saccharomyces boulardii in acute rotavirus diarrhea：double blind randomized controlled trial from a develo-ping country[J]. J Trop Pediatr，2016，62（6）：464-470.
MARKOVINOVIĆ L，KNEZOVIĆ I，KNIEWALD T，et al. Enteroadsorbent polymethylsiloxane polyhydrate vs. probiotic Lactobacillus reuteri DSM 17938 in the treatment of rotaviral gastroenteritis in infants and toddlers，a randomized controlled trial[J]. Front Pediatr，2020，8：553960.
MAHAPATRO S，MAHILARY N，SATAPATHY A K，et al. Nitazoxanide in acute rotavirus diarrhea：a randomized control trial from a developing country[J]. J Trop Med，2017，2017：7942515.
TERAN C G，TERAN-ESCALERA C N，VILLARROEL P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children：a randomized，single-blind，controlled trial in Bolivian children[J]. Int J Infect Dis，2009，13（4）：518-523.
HAGBOM M，NOVAK D，EKSTRÖM M，et al. Ondansetron treatment reduces rotavirus symptoms：a randomized double-blinded placebo-controlled trial[J]. PLoS One，2017，12（10）：e0186824.
GRANDY G，MEDINA M，SORIA R，et al. Probiotics in the treatment of acute rotavirus diarrhoea： a randomized，double-blind，controlled trial using two different probiotic preparations in Bolivian children[J]. BMC Infect Dis，2010，10：253.
KANG G，THUPPAL S V，SRINIVASAN R，et al. Racecadotril in the management of rotavirus and non-rotavirus diarrhea in under-five children：two randomized，double-blind，placebo-controlled trials[J]. Indian Pediatr，2016，53（7）：595-600.
SARKER S A，CASSWALL T H，JUNEJA L R，et al. Randomized，placebo-controlled，clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea[J]. J Pediatr Gastroenterol Nutr，2001，32（1）：19-25.
RAHMAN S，HIGO-MORIGUCHI K，HTUN K W，et al. Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients[J]. Vaccine，2012，30（31）：4661-4669.
PARK M S，KWON B，KU S，et al. The efficacy of Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 probiotic treatment in infants with rotavirus infection[J]. Nutrients，2017，9（8）：887.
DUBEY A P，RAJESHWARI K，CHAKRAVARTY A，et al. Use of VSL#3 in the treatment of rotavirus diarrhea in children：preliminary results[J]. J Clin Gastroenterol，2008，42（Suppl 3 Pt 1）：S126-S129.
LO VECCHIO A，NUNZIATA F，BRUZZESE D，et al. Rotavirus immunisation status affects the efficacy of Lacticaseibacillus rhamnosus GG for the treatment of children with acute diarrhoea：a meta-analysis[J]. Benef Microbes，2022，13（4）：283-294.
GUARINO A，CANANI R B，SPAGNUOLO M I，et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea[J]. J Pediatr Gastroenterol Nutr，1997，25（5）：516-519.
邵明义，张果，阎博华，等. 开放性/单盲设计临床试验质控现状的文献分析[J]. 中国全科医学，2010，13（12）：1372-1373.
ISANAKA S，LANGENDORF C，MCNEAL M M，et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger：extended follow-up of a randomized controlled trial[J]. PLoS Med，2021，18（7）：e1003655.
LIN S C，TAM K W，YEN J Y，et al. The impact of shared decision making with patient decision aids on the rotavirus vaccination rate in children：a randomized controlled trial[J]. Prev Med，2020，141：106244.
SUN Z W，FU Y，LU H L，et al. Association of rotavirus vaccines with reduction in rotavirus gastroenteritis in children younger than 5 years：a systematic review and meta-analysis of randomized clinical trials and observational studies[J]. JAMA Pediatr，2021，175（7）：e210347.
QIU C Y，GUO Z X，ZHANG G H，et al. Study on the effectiveness and safety of Xingpi Yanger Granule combined with Saccharomyces boulardii for rotavirus enteritis in children：a protocol for systematic review and meta-analysis[J]. Medicine，2021，100（16）：e25593.
0
Views
2
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.